Skip Navigation


Brain Advance Access originally published online on March 26, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
127/6/1219    most recent
awh145v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Peschanski, M.
Right arrow Articles by Hantraye, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peschanski, M.
Right arrow Articles by Hantraye, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 127, No. 6, 1219-1228, 2004
© 2004 Guarantors of Brain
doi: 10.1093/brain/awh145

Integrating fetal neural transplants into a therapeutic strategy: the example of Huntington’s disease

Marc Peschanski1, Anne-Catherine Bachoud-Lévi1,2 and Philippe Hantraye3

1 INSERM U 421, Faculté de Médecine, 2 Service de Neurologie, CHU Henri-Mondor, Créteil and 3 CEA-CNRS URA 2210, Unité d’Imagerie Isotopique, Biochimique et Pharmacologique UI2BP and ImaGene program, Service Hospitalier Frédéric Joliot, Orsay, France

Correspondence to: Marc Peschanski, INSERM U 421, Faculté de Médecine, 94010 Créteil cedex, France. E-mail: Peschanski{at}im3.inserm.fr

Fetal neural transplants have become clinically relevant over the past 15 years for two major neurodegenerative diseases, namely Parkinson’s disease and Huntington’s disease. It is therefore timely to consider how this neurosurgical procedure can integrate the therapeutic armamentarium, what can be expected of it, and what cannot. We use here the example of Huntington’s disease to show what fetal neural transplants may uniquely offer for that disease. Up to very recent times, Huntington’s disease has been one special example of those neurodegenerative diseases against which neurologists feel totally helpless. This has all changed today and, although results are essentially still to come, one can foresee the mobilization of very large scientific and medical forces against this disease, with definite steps forward in terms of physiopathology and a better view of the therapeutic challenges. While defining the role that fetal neural transplantation may play in meeting these challenges, we also try to show rationales and developments for all types of treatments attempted or suggested so far, as well as their limits and, when relevant, informative failures. The date of writing this review needs to be noted, because the rapid accumulation of data on molecular mechanisms of Huntington’s disease pathogenesis and the increasing numbers of clinical trials do not allow much time for the ink of a review to dry.

Key Words: neurodegenerative diseases; striatum; cell therapy; neuroprotection

Abbreviations: CNTF = ciliary neurotrophic factor

Received October 15, 2003. Revised January 9, 2004. Accepted January 10, 2004.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.